The Biorasi Project Team were focused on the completion of two critical project milestones which were suddenly put at risk due to the COVID-19 health crisis. Find out how the team were able to keep the project on track in our latest case study.
Biorasi is proud to announce the initiation of the company’s first COVID-19 clinical trial in May 2020. The U.S.-based trial will focus on the treatment for lung injuries caused by the COVID-19 virus.
Dr. Kurt Gehlsen, Chief Scientific Officer and Vice President of Medical and Scientific Affairs, has been appointed to the COVID-19 Rapid Response Funding panel at Science Foundation Ireland (SFI).
To our #sitepartners on the front lines, from all of us at Biorasi, thank you for everything you do to bring critical treatments to patients as we face #COVID19 together.
In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital. Without a proactive and comprehensive strategy in place to manage clinical trials over the coming weeks and maybe months, consequences may be severe –especially for those that need the treatment the most.
Business as usual is not an option for conducting #clinicaltrials in the wake of the #COVID19 pandemic. Customized solutions and #patientcentricity are more optimal approaches in this environment. Jimmy El Hokayem, Ph.D., Associate Director of Program Development and Head of the Neurology and Regenerative Medicine Center of Excellence at Biorasi, shares his insights into #directtopatienttrials
In this blog post, we will try to understand Virtual Clinical Trial. As technology continues to […]
How Virtual Trials Support Patient-Centricity: In this digital age, virtual trials may very well become the norm at some point in the future, but there are many questions to answer before this can become a reality.
